Current peptide vaccine and immunotherapy approaches against Alzheimer's disease

Parrocha, Chelsea Marie T.; Nowick, James S.

doi:10.1002/pep2.24289

Cited by 13 publications

(11 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Donanemab, another humanized mAb from Eli Lilly & Co., recognizing Aβ(p3-42) a pyroglutamate form of Aβ that is aggregated in amyloid plaques [ 63 , 64 , 65 ]. This humanized IgG1 antibody is currently being tested on AD patients with prodromal to moderate AD in a phase III clinical trial [ 66 , 67 ].…”

Section: Current Treatment Strategies Targeting Aβmentioning

confidence: 99%

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Vogt

Jennings²,

Mohsen

et al. 2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia and may contribute to 60–70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction is that the number will more than triple by 2050, as the population ages. Extracellular protein aggregation and plaque deposition as well as accumulation of intracellular neurofibrillary tangles, all leading to neurodegeneration, are the hallmarks of brains with Alzheimer’s disease. Therapeutic strategies including active and passive immunizations have been widely explored in the last two decades. Several compounds have shown promising results in many AD animal models. To date, only symptomatic treatments are available and because of the alarming epidemiological data, novel therapeutic strategies to prevent, mitigate, or delay the onset of AD are required. In this mini-review, we focus on our understanding of AD pathobiology and discuss current active and passive immunomodulating therapies targeting amyloid-β protein.

show abstract

Section: Current Treatment Strategies Targeting Aβmentioning

confidence: 99%

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Vogt

Jennings²,

Mohsen

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Another point to consider in forthcoming research relies on the fact that, even though the use of monoclonal antibodies as passive immunization against misfolded toxic proteins has been shown to be a suitable strategy for the treatment of NDDs (e.g., AD-related monoclonal antibodies: Aducanumab, Gantenerumab, Solanezumab, and Crenezumab) [ 152 , 153 , 154 , 155 ], plant-based expression systems have not yet been exploited for the production of these antibodies. Remarkably, emerging technologies have made it possible to obtain antibody production yields in whole plants of up to 2 g per kg of fresh weight [ 156 ], which portends a profitable future for the entry of this type of pharmaceutical product to the market.…”

Section: Future Directionsmentioning

confidence: 99%

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

Neurodegenerative diseases (NDDs) are characterized by the progressive degeneration and/or loss of neurons belonging to the central nervous system, and represent one of the major global health issues. Therefore, a number of immunotherapeutic approaches targeting the non-functional or toxic proteins that induce neurodegeneration in NDDs have been designed in the last decades. In this context, due to unprecedented advances in genetic engineering techniques and molecular farming technology, pioneering plant-based immunogenic antigen expression systems have been developed aiming to offer reliable alternatives to deal with important NDDs, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Diverse reports have evidenced that plant-made vaccines trigger significant immune responses in model animals, supported by the production of antibodies against the aberrant proteins expressed in the aforementioned NDDs. Moreover, these immunogenic tools have various advantages that make them a viable alternative for preventing and treating NDDs, such as high scalability, no risk of contamination with human pathogens, cold chain free production, and lower production costs. Hence, this article presents an overview of the current progress on plant-manufactured vaccines for NDDs and discusses its future prospects.

show abstract

“…Accumulating evidence suggests these monoclonal antibodies can potentially prevent tau’s cell-to-cell propagation and aggregation [ 65 ]. Janssen Research and Development ran two clinical trials in phase 1 to evaluate its safety and tolerability in participants [ 66 ]. The 2017 phase I clinical trial reported the monoclonal antibody to be safe and well tolerated [ 66 ].…”

Section: Tau Immunotherapiesmentioning

confidence: 99%

“…Janssen Research and Development ran two clinical trials in phase 1 to evaluate its safety and tolerability in participants [ 66 ]. The 2017 phase I clinical trial reported the monoclonal antibody to be safe and well tolerated [ 66 ]. In 2019, a phase I clinical trial reported dose-dependent increases in exposures.…”

Section: Tau Immunotherapiesmentioning

confidence: 99%

Therapeutics of Alzheimer’s Disease: Recent Developments

et al. 2022

View full text Add to dashboard Cite

With increasing aging, dementia is a growing public health concern globally. Patients with dementia have multiple psychological and behavioral changes, including depression, anxiety, inappropriate behavior, paranoia, agitation, and hallucinations. The major types of dementia are Alzheimer’s disease (AD), vascular dementia (VCID), Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia (MiAD). Among these, AD is the most common form of dementia in the elderly population. In the last three decades, tremendous progress has been made in understanding AD’s biology and disease progression, particularly its molecular basis, biomarker development, and drug discovery. Multiple cellular changes have been implicated in the progression of AD, including amyloid beta, phosphorylated tau, synaptic damage, mitochondrial dysfunction, deregulated microRNAs, inflammatory changes, hormonal deregulation, and others; based on these changes, therapeutic strategies have been developed, which are currently being tested in animal models and human clinical trials. The purpose of our article is to highlight recent therapeutic strategies’ developments, critically discuss current strategies’ failures, and propose new strategies to combat this devasting mental illness.

show abstract

Current peptide vaccine and immunotherapy approaches against Alzheimer's disease

Cited by 13 publications

References 68 publications

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases

Therapeutics of Alzheimer’s Disease: Recent Developments

Contact Info

Product

Resources

About